NEW YORK – Illumina and Emedgene announced on Wednesday a partnership on software for use in next-generation sequencing-based rare disease diagnosis.
Under the non-exclusive deal, the partners will integrate Emedgene's clinical rare disease application into Illumina's TruSight software suite. Financial and other terms of the agreement were not disclosed.
Emedgene, based in Palo Alto, California, offers software tools for automated genome interpretation in clinical and research use cases.